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IN 1848, DOCTORS AT THE HOSPITAL FOR 
Consumption and Diseases of the Chest in 
London undertook one of the world’s fi rst 
clinical trials. More than 1000 patients with 
tuberculosis (TB) were either just cared for, 
as no effective treatment was known, or were 
also given a spoonful of cod-liver oil three 
times a day. Nineteen percent of patients on 
cod-liver oil deteriorated or died, compared 
to 33% in the control group.
Before antibiotics became available in 
the mid-20th century, many TB patients were 
also sent to sanatoriums in Switzerland or 
other countries. Lying in their beds, they were 
wheeled out into the sun for phototherapy. 
Looking back, says Adrian 
Martineau, an immunolo-
gist at Barts and The London 
School of Medicine and Den-
tistry in London, the two experimental ther-
apies had something in common: vitamin D, 
which wasn’t discovered until 1922. 
Unlike other vitamins, the human body 
produces most of its vitamin D itself—with 
the help of sunshine. In the skin, a precur-
sor molecule called 7-dehydrocholesterol is 
turned into vitamin D3 by UV light. Ninety 
percent of vitamin D circulating in the human 
body is produced that way. Only 10% comes 
from food, in the United States and Canada 
mostly from milk, which is fortifi ed with the 
vitamin in those countries. It is also naturally 
abundant in some foods including fatty fi sh, 
sun-dried mushrooms—and cod-liver oil.  
Martineau has studied the connection 
between TB and vitamin D for years and has 
become convinced that the compound can not 
only help treat TB but also prevent it. He is 
part of a vocal camp of scientists who praise 
the powers of vitamin D and see it as some-
thing of a cure-all—or rather a prevent-all. 
In addition to its well-established benefi ts for 
bone health, they say vitamin D may—with 
little or no side effects—be able to ward off 
colds and other infections and cut the risk of 
asthma, diabetes, cancer, heart disease, and a 
slew of other chronic diseases.
Some of these scientists, such as Michael 
Holick, an endocrinologist at Boston Univer-
sity School of Medicine and 
a veteran of vitamin D stud-
ies, advocate fortifying more 
foods with the vitamin and 
advising people to take supplements and get 
more sun exposure. “Even if only one of these 
diseases turns out to be prevented by vitamin 
D, it is worth it,” he says. The public certainly 
seems to buy that argument. In the United 
States, sales of vitamin D supplements have 
increased from $50 million in 2005 to $600 
million in 2011, according to the Nutrition 
Business Journal. Ninety years after it was 
discovered, vitamin D seems to be enjoying its 
moment in the sun. 
But other researchers warn that the ben-
efi ts of vitamin D are far from proven. They 
also caution that its widespread use as a sup-
plement could do more harm than good, as 
trials of other vitamins have shown. Even 
a believer like Julian Peto, an epidemiolo-
gist at the London School of Hygiene and 
Tropical Medicine, cautions, “You have got 
to be very certain. Mass medication is not 
something you embark on lightly.” He adds: 
“What we know comes mainly from obser-
vational studies.”
In the next few years, however, the long-
standing vitamin D debate may fi nally be put 
to rest. In a number of large clinical trials, 
tens of thousands of people around the world 
will take a supplement or placebo pills in an 
effort to pin down the health benefi ts of the 
sunshine vitamin.
A body of evidence
Vitamin D was fi rst recognized for its role in 
bone health. It helps the body absorb calcium, 
and children who do not get enough of it can 
develop rickets, a bone-softening disease. But 
low vitamin D levels have also been impli-
cated in infectious diseases. For instance, 
patients with TB tend to have lower vitamin D 
levels, and Martineau points to studies show-
ing that the compound helps immune cells 
called macrophages kill the mycobacterium 
responsible for TB, as well as suppress the 
secretion of enzymes the pathogen uses to 
degrade lung tissue.  
In 2010, a randomized trial in 334 Jap-
anese schoolchildren found that those tak-
ing vitamin D supplements were less likely 
to suffer from an infl uenza infection. And 
in August, scientists from Harvard Medical 
School in Boston reported in Pediatrics that 
Mongolian schoolchildren whose milk was 
fortifi ed with vitamin D had half the risk of 
catching a cold compared to those drink-
ing unfortifi ed milk. It is perfectly plausible 
that lower vitamin D levels in winter might 
be the reason colds predominately circulate 
then, Peto says. 
Proponents of the sunshine vitamin have 
also amassed a variety of data suggesting it 
wards off asthma, diabetes, stroke, multiple 
sclerosis, and cognitive decline. And a body 
of evidence indicates vitamin D could cut 
the risk of cancer and cardiovascular dis-
ease dramatically, they argue. For colorec-
tal and breast cancer alone, raising vitamin 
D levels on a population level could pre-
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Boosting levels of vitamin D with supplements has been touted to prevent diseases, but 
many scientists say only clinical trials now in the works can confi rm such hopes
Ounce of prevention. Cod-liver oil has been given 
as preventative medicine for decades (left, British 
children in 1938 are presumably getting their spoon-
ful). Now scientists are amassing tens of thousands 
of volunteers to test the preventive power of one of 
its ingredients: vitamin D.
















































































vent more than 100,000 
cases each year and cut 
deaths from these diseases 
by three-fourths in the 
United States and Canada, 
a paper published in the 
Annals of Epidemiology 
in 2009 calculated.
One comprehensive 
review of the vitamin D 
literature, a meta-analysis 
published in 2011 by the 
Cochrane Collaboration, 
concluded that vitamin D3 
supplementation (but not 
other forms of the vita-
min) reduced overall mor-
tality by about 6% among 
the more than 90,000 peo-
ple in the 50 studies exam-
ined. “That is not overwhelming, but it is 
borderline signifi cant,” says Robert Scragg, 
a vitamin D researcher at the University of 
Auckland in New Zealand. 
Many vitamin D enthusiasts point to 
evolution to bolster their case. Dark skin 
protects skin cells from UV damage, but it 
also reduces the amount of vitamin D that is 
produced; African-Americans in the United 
States generally have lower levels of vita-
min D in the blood than the rest of the popu-
lation. “The strongest single bit of evidence 
[that more vitamin D is good for a person] is 
that humans turned white when they moved 
north,” Peto says. “That suggests low vita-
min D levels must have had [a negative] 
effect on survival.” 
Mass medication
However, some veteran vitamin researchers 
caution that other vitamins have been linked 
to a broad range of health benefi ts, only to 
have the evidence crumble upon closer 
examination. In the 1990s, for example, 
observational studies suggested that antiox-
idants such as beta carotene (a precursor of 
vitamin A) could shield the body from the 
cancer-causing compounds in tobacco and 
other harmful substances. But in 1994, a 
prospective clinical trial with nearly 30,000 
smokers in Finland concluded that those 
who had taken beta carotene supplements 
were actually 18% more likely to develop 
lung cancer and 8% more likely to die dur-
ing the trial. Two years later, a U.S. study 
examining vitamin A supplements in smok-
ers and asbestos workers was stopped early 
because there were 28% more lung cancers 
and 17% more deaths in the group receiving 
vitamin A than among the untreated.
Another antioxidant, vitamin E, was also 
touted as a cancer killer. But in 2008, a cancer-
prevention trial evaluating vitamin E and sele-
nium supplementation was stopped because 
participants taking vitamin E had become 
more likely to get prostate cancer. The risk dif-
ference then was not statistically signifi cant, 
but follow-up data published late last year 
showed a signifi cant increase of 17% com-
pared with the control group. 
Some predict that history is about to 
repeat itself. “I think vitamin D is going 
the way of these other treatments,” says 
Andrew Grey, a researcher at the University 
of Auckland. Low levels of vitamin D might 
simply be a marker of bad health rather than 
the cause of it, he suggests: “Almost always 
the levels are lower in patients who are 
sicker, but that could be because they exer-
cise less and do not go outside so much.” 
Another confounding factor: Vitamin D is 
fat-soluble, so obese patients also tend to 
have lower levels of circulating vitamin D. 
JoAnn Manson, an endocrinologist at 
Harvard Medical School, agrees that once 
again enthusiasm for a vitamin is outpac-
ing the evidence: “There are many reasons 
that low vitamin D levels might be linked to 
these chronic diseases. Correlation does not 
prove causation.” 
Other groups reviewing vitamin D data 
haven’t been as impressed as the Cochrane 
group. After sifting through hundreds of 
studies, a panel convened by the Institute 
of Medicine (IOM) concluded in 2010 that 
vitamin D was important for bone health, 
but that evidence did not support other ben-
efi ts from vitamin D intake.
Diffi cult dosing 
Tackling another contentious 
issue at the heart of the vitamin 
D debate, the IOM report also 
recommended an adequate blood 
level of the vitamin: 50 nmol/l. 
“Some people with malabsorp-
tion may need higher levels, 
but for the healthy population 
50 nmol per liter is certainly 
enough,” says Clifford Rosen, 
a bone-health expert at Maine 
Medical Center Research Insti-
tute in Scarborough, who was on 
the panel. The report also pointed 
out that most people in the United 
States reach that level through 
diet and sun exposure alone.
The strong vitamin D pro-
ponents, as well as other scien-
tists, say the IOM threshold is too low and 
hark back to prehistoric times to make their 
point. They argue that as humans started 
wearing clothes, developed sunscreens, 
and began spending many hours indoors, 
they cut themselves off from the level of 
vitamin D they used to have. Dutch sci-
entists published a study earlier this year 
examining vitamin D levels in two tribes 
in Tanzania. Living close to the equator, 
following a hunter-gatherer-like lifestyle, 
and not using sunscreen, the Maasai and 
Hazabe peoples had a mean serum con-
centration of 115 nmol/l. “That is probably 
where we all should be,” says Holick, who 
takes supplement pills to keep his vitamin 
D level between 100 and 150 nmol per liter. 
Others don’t aim as high, at least for keep-
ing the skeleton strong—the best studied 
aspect of vitamin D prevention science. “To 
ensure good bone health in everyone, you 
need to aim for a level of 75 nmol per liter,” 
says Michael Amling of the University Medi-
cal Center Hamburg-Eppendorf in Germany.
In a 2010 paper, Amling examined the 
bones and vitamin D levels of 675 people 
who had died in car accidents or of other 
unnatural causes. Seven of 82 people with a 
level above 50 nmol/l had weak bones. “That 
means almost 10% of the people with a serum 
level above this threshold have weak bones,” 
Amling says.
But the IOM panel, which had set itself 
the goal of allowing no more than 2.5% of 
the population to be at risk of brittle bones, 
used a different number: It divided the seven 
bodies with high vitamin D but low bone 
health by the total number of bodies: 675. 





















Vital sunshine. UV rays strik-
ing the skin convert the mol-
ecule 7-dehydrocholesterol to 
an inactive form of vitamin D3. 
It is then converted fi rst in the 
liver and then the kidneys to 
1,25-dihydroxyvitamin D3, the 






































Rosen warns that having higher blood lev-
els of vitamin D could be harmful. “I can actu-
ally live with 75 nmol per liter, but above that I 
am a little concerned,” he says. 
He and others cite a 2010 Australian 
study in which women aged 70 years or 
older were given a megadose of 500,000 
international units (IUs) once a year. Vita-
min D levels in their blood shot up to an 
average of 120 nmol/l, but these partici-
pants also fell and fractured their bones 
more often than those in the placebo group, 
the scientists reported. 
Proponents of vitamin D argue that such 
a megadose is unphysiological and that the 
study is a special case that should not be 
weighed too heavily in any risk-benefi t anal-
ysis. Rosen disagrees: “There is very little 
randomized clinical trial data that gets up to 
these levels, and there is just no evidence that 
it actually protects against skeletal problems 
or other diseases.”
Interjecting another note of caution, 
a paper published in the American Jour-
nal of Cardiology in January 2012 showed 
that vitamin D in the blood reduces infl am-
mation, measured by a protein called 
C-reactive protein (CRP)—until the vita-
min’s level reaches 50 nmol/l. Above that 
mark, the relationship reverses and more 
vitamin D increases CRP levels again. The 
authors concluded that supplementation 
with vitamin D to reduce infl ammation may 
be benefi cial only in those with low serum 
concentrations of the vitamin. 
Proving prevention
With the intent of resolving the usefulness of 
vitamin D, several investigators are launching 
large-scale trials to examine the benefi ts of 
vitamin D in a number of chronic diseases. In 
the VITAL study Harvard’s Manson leads, for 
example, 20,000 healthy people in the United 
States will receive either 2000 IUs of vitamin 
D a day or a placebo for 5 years. That should 
be enough to raise blood levels of vitamin D 
to 75 nmol/l or more in nearly all participants, 
she says. The trial will look at health outcomes 
as diverse as stroke, diabetes, cardiovascular 
disease, and cancer. The fi rst participants are 
already taking their pills, and the last ones 
should be recruited by the end of the year, 
Manson says. Similar studies are starting 
in Finland, New Zealand, and Switzerland; 
another one in the United Kingdom is in the 
pipeline (see table).
Such prevention trials are challenging—
and may not ultimately satisfy everyone. They 
must have large numbers of subjects and run 
for a long time, because enough participants 
need to develop a disease to see a difference 
between the two groups. That makes them 
very costly; the VITAL study, funded by the 
U.S. National Institutes of Health, will cost 
about $30 million. Compliance is also an issue, 
because healthy people taking part in a trial of 
vitamin D may be more likely to forget to take 
the pills than sick patients in a drug trial—
especially because there is no doctor admin-
istering the treatment in a clinic. In the VITAL 
study, participants will receive their pills in 
the mail once a month; in the Finnish study, 
the volunteers will be mailed 400 pills once a 
year. If many people forget to take their pills, 
that would make it harder to detect a difference 
between the treatment and control groups. 
There is another respect in which the vita-
min D trials differ from most other random-
ized clinical trials: Normally, the placebo 
group receives none of the compound being 
investigated, but participants in the placebo 
group of a vitamin D trial will still produce 
the vitamin in their skin and consume it with 
their food. That narrows the gap between the 
two groups. In addition, in all the ongoing 
trials, participants will be allowed to take 
low-dosed vitamin D supplements if they 
were already taking them. Holick sees that 
as a fatal fl aw in the VITAL study and oth-
ers: “They are essentially comparing 800 IUs 
a day with 2000 IUs.” The trial 
should have given the treat-
ment group 4000-IU supple-
ments to see a clear difference 
between it and the “control” 
group, he argues. But Manson 
points out that participants in 
both groups are allowed to take 
supplements. “The difference 
remains 2000 IUs,” she says.
The double-blind Finn-
ish study, which will start in 
a few months, will divide par-
ticipants into three groups of 
6000 that will take either a 
1600-IU vitamin D supple-
ment daily, 3200 IUs, or a pla-
cebo. And in the study in New 
Zealand, which in 2017 could 
be the first to report results, 
participants will take 100,000 
IUs or a placebo once a month.
Even these large studies may 
not be defi nitive enough on their own to settle 
the vitamin D issue, says Scragg, who heads 
the New Zealand study. He cites recent evi-
dence suggesting that vitamin D may only be 
benefi cial in those with low initial levels of the 
vitamin. That means proof of the effective-
ness of supplementation may only come from 
pooling the various studies, he says: “Then 
you could segment people into various vita-
min D ranges based on baseline levels and see 
whether it has an effect or not.” 
Until those data are in, and maybe even 
afterward, scientists will likely keep on argu-
ing, Rosen says. Evidence does not matter 
to many people when it comes to vitamin D, 
he maintains: “It is a religion. People really 
believe this stuff works.”
–KAI KUPFERSCHMIDT


























2000 IU D3 daily
1600 IU D3 daily or
3200 IU D3 daily
100,000 IU D3 a 
month 
(200,000 IU in June)
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